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a b s t r a c t  
Aim of this study was to investigate the involvement of the mitochondrial permeability transition pore 
(MPTP) and oxidative stress in the cardioprotective effect of vasopressin (AVP) on ischemia/reperfusion (I/ 
R) injury. Anesthetized male wistar rats were subjected to regional 30 min ischemia and 120 min 
reperfusion and randomly divided into nine groups: (1) Control; saline was administered intravenously 
before ischemia, (2) vasopressin was administrated 10 min prior to ischemia, (3, 4) Atractyloside as MPTP 
opener, was injected 5 min prior to reperfusion without and with vasopressin, (5, 6) Cyclosporine A as a 
MPTP closer, was injected 5 min prior to reperfusion without and with vasopressin, (7) mitochondria were 
isolated from control group and CaCl2 was added as MPTP opener and swelling inducer, (8) isolated 
mitochondria from Control hearts was incubated with Cyclosporine A before adding the CaCl2 (9) CaCl2 was 
added to isolated mitochondria from vasopressin group. Infusion of vasopressin decreased infarct size 
(18.671.7% vs. control group 37.672.4%), biochemical parameters [LDH (Lactate Dehydrogenase), CK-MB 
(Creatine Kinase-MB) and MDA (Malondialdehyde) plasma levels, PAB (Prooxidant–antioxidant balance)] 
compared to control group. Atactyloside suppressed the cardioprotective effect of vasopressin (32.571.9% 
vs. 18.671.7%) but administration of the Cyclosporine A without and with vasopressin signiﬁcantly reduced 
infarct size to 17.774% (P<0.001) and 22.773% (P<0.01) respectively, vs. 37.672.4% in control group. 
Also, vasopressin, similar to Cyclosporine A, led to decrease in CaCl2-induced swelling. It seems that 
vasopressin through antioxidant effect and MPTP inhibition has created a cardioprotection against ischemia/ 
reperfusion injuries. 
& 2015 Elsevier B.V. All rights reserved. 
1. Introduction 
Cardiac ischemia occurs frequently in critically ill patients and is 
associated with increased mortality (Lim et al., 2010). Cardiac pre­
conditioning represents the most potent and consistently reproducible 
method of rescuing heart tissue from undergoing irreversible ischemic 
damage. Unfortunately, the clinical value of ischemic preconditioning 
(IPC) is limited. None of the several identiﬁed pharmacologic agents 
that appear to limit reperfusion injury is available for clinical use (Yang 
et al., 2004). Vasopressin or arginine vasopressin (AVP) is essential for 
cardiovascular homeostasis (Holmes et al., 2001). Circulating levels of 
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AVP, which are elevated during hypovolemia and during cardiac stress, 
mediate important physiological functions such as osmotic regulation, 
vasoconstriction, and release of adrenocorticotropic hormone (ACTH) 
(Zhu et al., 2013). In the previous study we have shown that AVP 
(0.03 mg/rat) has protective effects on ischemia/reperfusion (I/R) 
induced myocardial injury in rat heart (Nazari et al., 2011). Interest­
ingly, other study conﬁrmed  the protective effects  of AVP in low  dose  
on myocardial injury of the ischemic reperfused heart (Pelletier et al., 
2013; Zhu et al., 2013). Also vasopressin infusion is cardioprotective in 
models of myocardial ischemia (Okamura et al., 1999) and  in  patients  
with postcardiotomy shock (Dunser et al., 2002). Moreover, we 
reported that AVP (0.03 mg/rat) provides cardioprotection against heart 
I/R injury by its anti-oxidant action (Nazari et al., 2011). However, 
the exact mechanisms of cardioprotection of AVP remain poorly 
understood. 
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Mitochondria are the most important cellular sources of 
reactive oxygen species production and are particularly suscepti­
ble to oxidative stress (Sastre et al., 2003). Indeed, conditions 
associated with post-ischemic reperfusion, such as reactive oxygen 
species accumulation, pH normalization and increases in [Ca2 þ ], 
create an ideal scenario for mitochondrial permeability transition 
pore (MPTP) opening (Zoratti and Szabo, 1995). Opening of the 
MPTP may result in mitochondrial swelling, collapse of mitochon­
drial membrane potential, uncoupling of mitochondrial oxidative 
phosphorylation and cytochrome C release, leading to both necro­
sis and apoptosis. It was demonstrated that preventing MPTP 
opening may be protective in isolated cardiomyocytes (Nazareth 
et al., 1991) and perfused hearts (Grifﬁths and Halestrap, 1993). In 
addition, modulation of MPTP opening has been observed in 
cardioprotection by both preconditioning (Xu et al., 2001) and 
post-conditioning (Argaud et al., 2005) of the heart. Inhibition of 
MPTP opening also exerts cardioprotection against I/R injury in 
mice induced in vivo (Wang et al., 2005). 
The purpose of the present study was to determine whether 
AVP protects the heart at reperfusion through a mitochondrial 
pathway, speciﬁcally via inhibition of MPTP opening. 
2. Materials and methods 
Male Wistar rats (Weighing 280–310 gr) housed under stan­
dardized conditions 12-h light/dark cycle, 20–22 1C ambient tem­
perature and 40–50% humidity with free access to fed standard rat 
chow and tap water. All animal care and experiments were 
conducted in accordance with the institutional guidelines of 
Tehran University of Medical Sciences (Tehran, Iran). 
2.1. Surgical preparation 
Anesthesia was achieved by administration of sodium thiopental 
(60 mg/kg, i.p.). Body temperature was maintained at 3771 1C. After a 
tracheotomy, all rats were ventilated with air and oxygen mixture by 
Parvalux rodent respirator (15 ml/kg stroke volume and 60–70 Breaths/ 
min). The right carotid artery was dissected and a heparinized saline 
(100 U/ml) ﬁlled polyethylene-tubing catheter (PE-50) was inserted 
into the artery for blood sampling and hemodynamic monitoring. The 
femoral vein was cannulated to inject Evans blue and drugs. Lead-II 
electrocardiogram (ECG) and arterial hemodynamic parameters were 
continuously monitored and recorded throughout the experiment, 
using a computerized data acquisition system (ML750 PowerLab/4sp, 
AD Instruments). 10 min prior to the end of reperfusion period, the 
carotidal catheter was advanced to the Left Ventricle (LV) to record the 
functional parameters of LV (Smith et al., 1979). 
Rats were given heparin (200 IU/kg, i.v.), and then the chest 
was opened by a left thoracotomy in the fourth rib to expose the 
heart. The pericardium was incised and a 6–0 silk suture was 
placed around the left anterior descending coronary artery (LAD) 
close to its origin. Both ends of the suture were passed through 
coronary ligator. Heart rate and blood pressure were allowed to 
stabilize for 15 min before the intervention protocols. Applying 
tension to the suture by ligator caused regional ischemia, and 
reperfusion was achieved by releasing the tension on the ligature. 
Ischemia was conﬁrmed by ST elevation in ECG, or cardiac cyanosis 
subsequent decrease in blood pressure, and reperfusion was 
conﬁrmed by epicardial hyperemia. 
2.2. Experimental protocol 
After a stabilization period following the surgical preparation, 
basal hemodynamic parameters were measured for 15 min before 
drug administration and the heart of all animals was subjected to 
30 min ischemia and 120 min reperfusion (Fig. 1). Rats were 
randomly divided into nine groups: (1) Control; saline was 
administered intravenously before ischemia, (2) AVP0.03; vaso­
pressin 0.03 mg/rat was infused within 10 min prior to ischemia 
(n¼13), (3, 4) Atr and AVPþAtr; Atractyloside (5 mg/kg, i.v.), as a 
MPTP opener, was injected 5 min prior to reperfusion without and 
with the effective dose of AVP 0.03 mg/rat into two different groups 
(n¼13), (5, 6) CsA and AVPþCsA Cyclosporine A (CsA, 5 mg/kg, 
i.v.), as a MPTP closer, was injected 5 min prior to reperfusion 
without and with the effective dose of AVP (0.03 mg/rat) into two 
different groups (n¼13). (7) Control–CaCl2; mitochondria were 
isolated from control group and 200 mmol/l CaCl2 was added to 
induce MPTP opening and swelling (n¼4), (8) CsA–CaCl2; an  
aliquot of mitochondria from Control hearts was incubated with 
1 mmol/l CsA for 2 min before the addition of 200 mmol/l CaCl2 
(n¼4) (9) AVP–CaCl2; mitochondria were isolated from AVP0.03 
group and 200 mmol/l CaCl2 was added to examine mitochondrial 
swelling (n¼4). 
2.3. Hemodynamic functions 
Arterial blood pressure and heart rate (HR) were continuously 
monitored and recorded throughout the experiment. Left ventri­
cular hemodynamic parameters such as Left ventricular End-
Diastolic Pressure (LVEDP), left ventricular developed pressure 
[LVDP¼LVSP (Left ventricular systolic pressure)-LVEDP], max­
imum rise and fall of LV pressures (þdp/dt and -dp/dt respec­
tively) and RPP (Rate pressure product¼LVDP x HR) were 
recorded at 10 min of end reperfusion. 
2.4. Cardiac area at risk and infarct size determination 
At the end of reperfusion, the coronary artery was reoccluded 
and 2 ml of Evans blue (2%) was injected intravenously to the 
femoral vein. Then, the heart was excised, cut into 2 mm slices. All 
slices were incubated with a 1% 2,3,5-triphenyltetrazolium chlor­
ide (TTC, in 0.1 M phosphate buffer, pH 7.4) stain for 15 min at 
37 1C, to visualize the infarct area. Then they were ﬁxed in 10% 
formalin to enhance the contrast of the Evans blue and TTC 
staining. Both surfaces of each section were scanned using Photo-
shop program (Adobe Systems, version 7.0). Total area at risk was 
expressed as a percentage of the left ventricles (AAR/LV). Infarct 
size was expressed as a percentage of the area at risk (IS/AAR). 
2.5. Biochemical analysis 
Blood samples were collected at the end of reperfusion for measure­
ment of the cardiac enzymes, including creatine kinase-MB (CK-MB), 
lactate dehydrogenase (LDH) and Malondialdehyde (MDA). The hepar­
inized samples were centrifuged at 5000g, for 15 min, and the plasma 
was removed and stored at -70 1C until  the time they were assayed.  
The activity of CK-MB and LDH were analyzed using commercial kits 
(Pars Azmoon, Iran) by employing an autoanalyzer (Roche Hitachi 
Modular DP Systems, Mannheim, Germany). MDA content of samples 
was determined spectrophotometrically using a modiﬁcation of the 
assay described by Schuh et al. (1978). 
2.6. Prooxidant–antioxidant balance (PAB) assay 
Amodiﬁed PAB was applied based on a previously described method 
(Alamdari et al., 2007). The standard solutions were prepared by mixing 
varying proportions (0–100%) of 250 mM hydrogen peroxide with 3 mM 
uric acid (in 10 mM NaOH). 60 mg TMB (3,30,5,50-Tetramethylbenzidine) 
powder was dissolved in 10 ml DMSO; for preparation of TMB cation, 
400 ml of TMB/DMSO was  added in 20  ml of acetate  buffer  [0.05  M  
buffer, pH 4.5], and then 70 ml of fresh chloramine T (100 mM) solution 
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was added into this 20 ml, mixed well, incubated for 2 h at room 
temperature in a dark  place;  25  U of peroxidase enzyme solution  was  
added into 20 ml TMB cation, dispensed in 1 ml and put at -20 1C; in 
order to prepare the TMB solution 200 ml of TMB/DMSO was added into 
10 ml of acetate buffer [0.05 M buffer, pH 5.8]; the working solution was 
prepared by mixing 1 ml TMB cation with 10 ml of TMB solution, 
incubated for 2 min at room temperature in a dark place and immedi­
ately used. Ten microliters of each sample, standard or blank (distilled 
water) were mixed with 200 ml  of working  solution, in each well  of a 96  
well plate, which was then incubated in a dark place at 37 1C for  12min;  
at the end of the incubation time, 100 ml of 2 N HCl was added to each 
well; and measured in an ELISA reader at 450 nm with a reference 
wavelength of 620 or 570 nm. A standard curve was provided from the 
values relative to the standard samples. The values of the PAB are 
expressed in arbitrary HK units, which are the percentage of hydrogen 
peroxide in the standard solution. The values of the unknown samples 
were then calculated based on the values obtained from the above 
standard curve. 
2.7. Preparation of mitochondria 
Mitochondria were isolated from male rats by differential 
centrifugation with some modiﬁcations (Ghazi-Khansari and 
Mohammadi-Bardbori, 2007). In brief, after deep anesthesia, the 
Fig. 1. Illustration of the experimental groups. Animals in control group were subjected to 30 min ischemia followed by 120 min reperfusion and saline was administered 
intravenously before ischemia, (group 2) AVP0.03; effective doses of vasopressin (0.03 μg/rat) was infused within 10 min prior to ischemia, (groups 3, 4) Atr and AVPþAtr; 
Atractyloside (5 mg/kg, i.v.), as a MPTP opener, was injected 5 min prior to reperfusion without and with the effective dose of AVP (0.03 mg/rat) into two different groups, 
(groups 5, 6) CsA and AVPþCsA; Cyclosporine A (CsA, 5 mg/kg, i.v.), as a MPTP closer, was injected 5 min prior to reperfusion without and with the effective dose of AVP 
(0.03 mg/rat) into two different groups. NS, normal saline; TTC, triphenyltetrazolium chloride (n¼13). 
Table 1 
Hemodynamic parameters. 
Groups Baseline End of ischemia 300 End of reperfusion 600 End of reperfusion 1100 
HR SAP HR SAP HR SAP HR SAP 
Control 
AVP0.03 
Atr 
AVP þAtr 
CsA 
AVP þCsA 
308712 
312718 
376716 
334711 
334727 
340710 
109 75 
110 77 
127 76 
12875 
12975 
12473 
290715 
304714 
354713 
338710 
316725 
324718 
9775 
9775 
11973 
11774 
11076 
108 74a 
269714a 
293715 
351722c 
340711c 
322717 
324715 
9274a 
8772a 
100 75a 
10477e 
11275c 
10775a 
233712b 
293719c 
357713d 
331712d 
305714f 
314715f 
76 75b 
8575b 
9577b 
84711b 
9575a 
9675b 
The values are mean7S.E.M. HR, heart rate (beats/min); SAP, systolic arterial pressure (mmHg); AVP, arginine vasopressin; Atr, Atractyloside; CsA, Cyclosporine A. 
a Po0.01 vs. Its baseline within group.
 
b Po0.001 vs. Its baseline within group.
 
c Po0.05 vs. Control.
 
d Po0.001 vs. Control.
 
e Po0.05 vs. Its baseline within group.
 
f Po0.01 vs. Control.
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hearts immediately excised and AAR (area at risk) zone from LV 
was minced by small scissor in an ice cold manitol solution 
containing 0.255 M D-manitol, 74 mM sucrose and 0.2 mM ethy­
lenediaminetetraacetic acid (EDTA) (pH¼7.4). Then the minced 
tissue was gently homogenized in a glass homogenizer with a 
Teﬂon pestle and then centrifuged at 1500g for 10 min at 4 1C to  
remove nuclei, unbroken cells and other non-subcellular tissues. 
The supernatants were centrifuged at 10,000g for 10 min at 4 1C. 
The pellet was resuspended in 1 ml of respiration buffer (70 mM 
sucrose, 230 mM manitol, 3 mM HEPES, 2 mM Tris–phosphate, 
5 mM succinate and 1 mM of rotenone) (pH¼7.4) for the determi­
nation of mitochondrial swelling. 
2.8. Protein concentration 
Mitochondrial protein concentrations were determined using 
the method developed by Bradford (1976). 
2.9. Mitochondrial swelling assays 
Opening of the MPTP causes mitochondrial swelling and the 
change in mitochondrial volume due to colloidal osmotic effects of 
solute ﬂux into and out of the mitochondrial matrix was measured 
by monitoring the absorbance at 520 nm (A520) as described (Zhao 
et al., 2010). Brieﬂy, isolated mitochondria (approximately 500 mg) 
in 1 ml of respiration buffer were pre-incubated at 30 1C for 
10 min. After a 10 min equilibration period, 200 mmol/l CaCl2 
was added to induce MPTP opening (Baines et al., 2003). Absor­
bance was measured spectrophotometrically at 520 nm for 21 min 
at 3 min time intervals. 
2.10. Materials 
All chemicals used were obtained from Sigma Chemical Co. 
2.11. Statistical analysis 
Statistical analysis of arterial hemodynamic parameters within 
groups was performed with repeated measures ANOVA followed by 
Tukey's test and One-way ANOVA followed by Tukey's test was used 
to determine statistical signiﬁcance in all other cases. All data were 
expressed as mean7S.E.M. Statistical signiﬁcance was deﬁned as 
Po0.05. 
3. Results 
3.1. Hemodynamic functions 
Tables 1 and 2 demonstrate the time course of heart rate and 
systolic arterial pressure (SAP) during the experiments. There were 
Table 2 
Hemodynamic parameters changes. 
no signiﬁcant differences among groups at baseline before treat­
ment. At the end of 60 min and 120 min reperfusion, heart 
function was signiﬁcantly decreased in control group, as indicated 
by SAP and HR as compared with its baseline. Atractyloside and 
Cyclosporine A in (AVPþAtr) and (AVPþCsA) groups signiﬁcantly 
prevented the decrease in HR at the end of 60 min and 120 min 
reperfusion compared to their baseline, but had no effect on SAP. 
SAP not only decreased in CsA group at the end 60 min reperfusion 
but also signiﬁcantly increased that compared to control group. As 
shown in Table 3, Atr and AVPþCsA caused signiﬁcantly increasing 
in RPP compared to control. Moreover Atr caused signiﬁcantly 
increasing in -dp/dt compared to control. There were no sig­
niﬁcant differences of intraventricular parameters between any 
other groups. 
3.2. Area at risk and infarct size measurements 
There were no signiﬁcant differences in AAR/LV among groups. 
Infarct size was 37.672.4% in control group, whereas AVP 0.03 mg/ 
rat signiﬁcantly reduced infarct size to 18.671.7 vs. control group 
(Fig. 2). The reduction in infarct size by AVP 0.03 was abolished by 
Atractyloside infusion in AVPþAtr group as compared to AVP0.03 
(32.571.9% vs. 18.671.7%) and Cyclosporine A administration in 
CsA and AVPþCsA groups signiﬁcantly reduced infarct size to 
17.7 74% (Po0.001) and 22.773% (Po0.01) respectively, vs. 
37.6 72.4% in control group and returned infarct size as seen as 
in AVP0.03. 
3.3. Biochemical analysis 
3.3.1. LDH and CK-MB activity 
Compared to control group, administration of AVP 0.03 mg/rat 
could prevent elevation of LDH activity in plasma after ischemia/ 
reperfusion injury. Also AVP 0.03 signiﬁcantly reduced CK-MB 
Table 3 
Intraventricular hemodynamic parameters at 10 min of end reperfusion. 
Groups LVDP LVEDP RPP þdp/dt -dp/dt 
Control 7475 4.070.8 17,53971784 20297147 -16387127
 
AVP0.03 8177  1.670.4 23,61672971 21957254 -19687236
 
Atr 9079 6.271.2 33,06873722a 25577189 -25487160b
 
AVPþAtr 80711 3.870.3 26,86474190 22867325 -2155 7317
 
CsA 9673 3.870.9 28,91872357 26047136 -24187155
 
AVPþCsA 9376  4.170.8 30,54572771b 25687159 -23817165
 
The values are mean7S.E.M; AVP, arginine vasopressin; Atr, Atractyloside; CsA, 
Cyclosporine A; LVDP, left ventricular developed pressure (mmHg); LVEDP, left 
ventricle end-diastolic pressure (mmHg); RPP, rate pressure product (beats/ 
min mmHg x 103); the maximum rise and fall of LV pressures (þdp/dt and -dp/ 
dt, respectively) (mmHg/s). 
a Po0.01 vs. Control. 
b Po0.05 vs. Control. 
Groups Δ1 Change Δ2 Change Δ3 Change 
HR SAP HR SAP HR SAP 
Control 
AVP0.03 
Atr 
AVP þAtr 
CsA 
AVP þCsA 
-11.0475.3 
-7.5178 
-22.976.2 
4.5878.1 
-0.5779.3 
-0.52713.2 
-11.7473.1 
-1373.9 
-8.876.7 
-15.1 78 
-22.377.2 
-16.172.5 
-33.6477.8 
-18.74711.3 
-25711.9 
-16.9717.7 
-12.42712.4 
-1.6577.7 
-17.1 74 
-23.377.2 
-27.1 77.6 
-27.9 78.9 
-21.2 77.9 
-16.874.9 
-56.05710.7 
-8.55717.3 
-19.877.7 
10.14711.3 
-29.9715.7 
-10.49712.3 
-33.2775.8 
-25.774.8 
-32.476.3 
-48.6712.5 
-37.7 76.3 
-27.9 73.6 
The values are mean7S.E.M. HR, heart rate (beats/min); SAP, systolic arterial pressure (mmHg); AVP, arginine vasopressin; Atr, Atractyloside; CsA, Cyclosporine A. Δ1 
Changes: differences between end of ischemia 30 and end of baseline period, Δ2 changes: differences between end of reperfusion 60 and end of baseline period, Δ3 changes: 
differences between end of reperfusion 110 and end of baseline period. 
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level as compared to control group. Atractyloside and Cyclosporine 
A infusion in AVPþAtr and AVPþCsA groups signiﬁcantly returned 
LDH and CK-MB plasma level as seen as in control group (Table 4). 
3.3.2. Lipid peroxidation level 
MDA plasma level in AVP 0.03 group signiﬁcantly declined 
compared to control group. Administration of Atractyloside and 
Cyclosporine A prior to reperfusion in AVPþAtr and AVPþCsA 
groups returned MDA plasma level as shown in control (Table 4). 
3.4. PAB assay 
The PAB  value of control  group was 46.873 (HK  unit)  (Fig. 3). 
Compared to control group, administration of AVP 0.03 mg/rat 
(11.170.5 HK, Po0.001) could prevent the elevation of PAB value in 
plasma after ischemia/reperfusion injury and Compared to AVP 0.03 
group, Atractyloside and Cyclosporine A in AVPþAtr (45.974.6 HK, 
Po0.001) and AVPþCsA (47.471.9 HK, Po0.001) groups signiﬁcantly 
increased PAB value and returned its level as seen as in control group. 
3.5. Mitochondrial swelling assays 
To determine whether AVP can modulate MPTP opening, we 
tested the effect of AVP on the decrease of A520 in isolated 
Fig. 2. Myocardial area at risk (AAR/LV %) and infarct size (IS/AAR %) in Control, AVP 
(0.03 mg/rat), Atr, AVP (0.03 mg/rat)þAtr, CsA and AVP (0.03 mg/rat)þCsA groups. 
Data are presented as mean7S.E.M. AVP, arginine vasopressin; Atr, Atractyloside; 
#CsA, Cyclosporine A. nnPo0.01, nnnPo0.001 vs. control group. Po0.05 vs. 
AVP0.03 (n¼13). 
Table 4 
The plasma levels of LDH, CK-MB and MDA at the end of reperfusion in Control, AVP 
(0.03 mg/rat), Atr, AVP (0.03 mg/rat)þAtr, CsA and AVP (0.03 mg/rat)þCsA groups. 
Groups LDH (IU/dl) CK-MB (IU/dl) MDA (nmol/ml) 
Control 367723.3 27.972.9 4.170.2 
AVP0.03 182721.1a 9.7871.2b 2.170.3a 
Atr 6727124.8 14.971.2c 2.770.4a 
AVP þAtr 
CsA 
4537103.5d 
460766.6 
28.677.4e 
18.871.9 
3.070.4 
3.670.6 
AVP þCsA 6357106.9f 38.778.2f 3.471.4 
The values are expressed as mean7S.E.M; AVP, arginine vasopressin; Atr, Atracty­
loside; CsA, Cyclosporine A; LDH, lactate dehydrogenase; CK-MB, creatine kinase-
MB; MDA, malondialdehyde. 
a Po0.01 vs. Control.
 
b Po0.001 vs. Control.
 
c Po0.05 vs. Control.
 
d Po0.05 vs. AVP0.03.
 
e Po0.01 vs. AVP0.03.
 
f Po0.001 vs. AVP0.03.
 
mitochondria. This was used to indicate swelling of the mitochon­
drion as a result of opening of the pore. At 200 mmol/L, CaCl2, which  
is known to open the pore, evoked a large decrease in A520. This  
effect was inhibited by 1 mmol/L CsA, conﬁrming that the decrease 
in absorbance was due to pore opening. Interestingly, AVP0.03 mg/ 
rat in AVP0.03 group also inhibited the decrease in A520, suggesting 
that it may protect the heart by inhibiting pore opening (Fig. 4). 
4. Discussion 
In the previous work, we showed that AVP can induce pre­
conditioning in a dose-dependent manner via V1 receptor (Nazari 
et al., 2011). 
The present study revealed that exogenous AVP (0.03 μg/rat) can 
induce preconditioning and signiﬁcantly decreased infarct size, 
Biochemical parameters (LDH, CK-MB and MDA plasma levels) and 
PAB as compared to control group and Administration of Atractylo­
side (as MPTP opener), decreased the cardioprotective effects  of AVP.  
It seems that the cardioprotective effect of AVP against myo­
cardial infarction was mediated via inhibiting of MPTP perme­
ability. Many studies have shown a role for mitochondria in 
reperfusion injury (Rajesh et al., 2003). The mitochondrial perme­
ability transition pore (MPTP) is transmembrane protein that play 
a major role in both necrotic and apoptotic cell death. The major 
components of the MPTP are the adenine nucleotide translocase 
(ANT) in the inner membrane of the mitochondria, cyclophilin D in 
Fig. 3. The PAB value of Control, AVP (0.03 mg/rat), Atr, AVP (0.03 mg/rat)þAtr, CsA 
and AVP (0.03 mg/rat)þCsA groups. AVP, arginine vasopressin; Atr, Atractyloside; 
CsA, Cyclosporine A. Data are presented as mean7S.E.M. nnnPo0.001 vs. control 
group. ### Po0.001 vs. AVP0.03 group (n¼13). 
Fig. 4. Percentage reduction in the rate of absorption at 520 nm (A520) in Control– 
CaCl2, CsA–CaCl2 and AVP–CaCl2 groups in suspensions of rat heart mitochondria 
exposed to 200 mmol/L CaCl2. Mitochondria from control group that treated with 
200 mmol/L CaCl2 served as the Control–CaCl2. Absorbance data 21 min after 
addition of 200 mmol/L CaCl2. Data are the mean7S.E.M. nPo0.05 compared with 
Control–CaCl2 (n¼4). 
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the matrix and the voltage dependent anion channel (VDAC) in the 
outer membrane. These proteins are thought to come together at 
intermembrane junctions to form the MPTP (Halestrap and 
Brenner, 2003). Under normal physiological conditions, the mito­
chondrial inner membrane is impermeable. However, under stress, 
a nonspeciﬁc pore known as the MPTP can open in the mitochon­
drial inner membrane that allows free passage of any molecule of 
o1.5 kDa (Halestrap et al., 2004). The key factor responsible for 
MPTP opening is mitochondrial calcium overload, especially when 
this is accompanied by oxidative stress, adenine nucleotide deple­
tion, elevated phosphate concentrations, and mitochondrial depo­
larization (Halestrap et al., 2004). 
Increased free oxygen radicals cause tissue damage through the 
peroxidation of the lipids present in the cell membranes and 
increasing lipid peroxidation might be used as a sign of the tissue 
damage. MDA is the ﬁnal product of lipid peroxidation and is used as 
an indicator of tissue damage caused by oxygen free radicals (Kim 
et al., 2000; Molina and Garcia, 1997; Sahin et al., 2011). Current data 
show that plasma level of MDA signiﬁcantly reduced following 
exogenous administration of AVP compared to control group more­
over caused decrease of the PAB value in favor of the antioxidant 
status and Atractyloside in AVPþAtr group signiﬁcantly increased 
PAB value and returned its level to oxidant status as seen as in control 
group. A signiﬁcant amount of evidence is present in the literature to 
support the role of oxygen free radicals in pathogenesis of I/R injury 
(Das et al., 1986; Tosaki et al., 1993). This receives further support from 
the evidence that a variety of free radical scavengers and antioxidants 
are capable of ameliorating I/R injury (Das and Maulik, 1994). In 
addition, it has been demonstrated that NO plays a crucial role in 
cardiac preconditioning. NO production was associated with myocar­
dial preservation during ischemia (Imani et al., 2011; Maulik et al., 
1995). Martinez et al. (2003) reported that the modulatory role of NO 
in  the coronary response to  AVP  may  be preserved  during partial  
coronary occlusion in anesthetized goats. Therefore, it seems that AVP 
via NO production could induce cardioprotection against I/R injury. 
Many studies have shown a role for mitochondria in reperfusion 
injury following ischemia. During reperfusion, cellular calcium 
increases, resulting in opening of the MPTP and release of cyto­
chrome C. Subsequent activation of caspases results in the failure of 
ATP generation and mitochondrial membrane potential and leads to 
cell death (Rajesh et al., 2003). Studies have shown that IPC inhibits 
a process occurring during ischemia and reperfusion that is respon­
sible for sensitizing the MPTP to calcium and reduced MPTP 
opening at the onset of reperfusion and exerts its protective effects 
(Halestrap et al., 2007). So it seems that MPTP is one of the major 
pathways and main effectors in cardioprotection following precon­
dition period. Atractyloside induces pore formation by ANT, and 
results in permeabilization of MPTP, causing uncoupling of oxidative 
phosphorylation (Xu et al., 2001) and abolished the beneﬁcial effect 
of preconditioning (Hausenloy and Yellon, 2007). The current study 
has shown that AVP owns a cardioprotective effect via myocyte 
mitochondria against I/R injury in rat in vivo. 
The present study has shown that Cyclosporine A similar to AVP 
signiﬁcantly reduced infarct size vs. control group but in other factors 
included: biochemical parameters (LDH, CK-MB and MDA) and PAB 
value, we did not see any cardioprotective effects. Moreover CsA 
caused increase of the PAB value in favor of the oxidant status. 
Cyclosporine A (CsA) is a well-known immunosuppressant, but 
also a potent inhibitor of MPTP opening and is considered to be 
inherently protective in conditions of ischemia, e.g. in cardiac tissue. 
There are several hypotheses to explain the mechanism of CsA­
induced adverse effects, including the formation of free oxygen 
radicals, lipid peroxidation and induction of the cytochrome P450 
system (Bianchi et al., 2003; Wang and Salahudeen, 1995; Zachariae, 
1999). Several reports have suggested that oxidative stress is the most 
possible pathway of CsA toxicity (Grieve and Shah, 2003; Rezzani 
et al., 2003). 
CsA due to MPTP inhibition regardless of its oxidant properties 
has been used in heart ischemia–reperfusion studies and had 
more beneﬁcial effects (as MPTP inhibitor). In other study CsA 
(10 mg/kg) was given 10 min prior to ischemia via the femoral 
vein. CsA signiﬁcantly reduced infarct size and decreased caspase­
3 activity in the myocardium and relieved the injury of mitochon­
dria. CsA reduced the cardiac damage associated with ischemia– 
reperfusion injury of the heart. The cardioprotective effects of CsA 
might be associated with the protection of mitochondria and the 
inhibition of caspase-3 activity (Xie and Yu, 2007). 
CsA caused SAP not only decreased at the end 60 min reperfusion 
but also signiﬁcantly increased that compared to control group. Rezzani 
et al. had shown that CsA had adverse effect including increased blood 
pressure (Rezzani, 2004) that was mediated via increased synthesis of 
vasoconstrictor eicosanoids (Bianchi et al., 2003). Exogenous AVP in 
both groups of (AVPþAtr) and (AVPþCsA) prevented the decrease in 
HR at the end of reperfusion compared to their baseline. It seems that 
this effect not related to opening and closing of MPTP and probably is 
done by other pathways that remain to be explored in future studies. 
Opening of the MPTP may result in mitochondrial swelling, collapse of 
mitochondrial membrane potential, uncoupling of mitochondrial oxi­
dative phosphorylation and cytochrome C release, leading to both 
necrosis and apoptosis. It was demonstrated that modulation of MPTP 
opening has been observed in cardioprotection by both precondition­
ing and post-conditioning of the heart (Liu et al., 2008). Mitochondria 
isolated from AVP–CaCl2 group showed reduced swelling to challenge 
with 200 mmol/L CaCl2. Furthermore, these mitochondria showed a 
degree of swelling similar to that induced by CsA. Therefore, it may be 
suggested that AVP owns a cardioprotective effect against I/R injury by 
inhibiting MPTP opening. Although the mechanism of the action of AVP 
in preconditioning responses was not completely explored in my 
previous (Nazari et al., 2011) and present study, but it had shown that 
mainly direct activation of V1 receptors on cardiac myocyte can active 
intracellular signaling specially inhibiting MPTP opening and events 
previously described (Briley et al., 1994; Dayanithi et al., 2008) similar  
to preconditioning signaling (Starkopf et al., 1998). Another possibility 
to consider is that AVP reduced free radical formation in the hearts and 
ﬁnally by inhibiting MPTP opening on cardiac tissue may be the cause 
of its protection. Thus, AVP may induce preconditioning via several 
different mechanisms. However, the exact mechanism(s) behind the 
cardioprotective effects of AVP remain to be explored in future studies. 
Further studies are needed to truly disentangle the cardiopro­
tective mechanism of AVP against ischemia–reperfusion injury 
that included: 
a- The cardioprotective effect of endogenous vasopressin (AVP) 
against ischemia–reperfusion injuries in the anesthetized 
rat heart. 
b- Myocardial expression of V1 receptor in condition of ischemia– 
reperfusion injuries. 
c- Examined the relationship between oxytocin receptors and 
vasopressin in condition of heart ischemia–reperfusion. 
d- The molecular mechanisms of mitochondria responsible for the 
cardioprotective effect of AVP such as: apoptotic factors expres­
sion, myocardial ATP content, the release of cytochrome c, etc. 
5. Conclusion 
The present study exhibited that exogenous AVP had hormonal 
preconditioning effect mainly via antioxidant effect and probably 
by inhibiting MPTP opening on cardiac myocyte against ischemia/ 
reperfusion injury in rat heart in vivo. 
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